Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05355753
Other study ID # CFT8634-1101
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date March 25, 2022
Est. completion date December 19, 2023

Study information

Verified date January 2024
Source C4 Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, non-randomized, first-in-human Phase 1/2 study designed to evaluate the safety and tolerability of CFT8634 in subjects with synovial sarcoma and SMARCB1-null tumors who: have received prior systemic therapy; have relapsed/refractory tumors; have unresectable or metastatic disease; and are not candidates for available therapies known to confer clinical benefit. The study will characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of CFT8634.


Recruitment information / eligibility

Status Terminated
Enrollment 50
Est. completion date December 19, 2023
Est. primary completion date December 19, 2023
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: 1. Subject (and legal guardian where applicable) is (are) willing and able to provide signed informed consent (or assent, where applicable) and can follow protocol requirements 2. Subject has histologically or cytologically confirmed synovial sarcoma or SMARCB1-null sold tumor that is relapsed/refractory, and unresectable or metastatic; the subject must not be a candidate for available therapies that are known to confer clinical benefit a. Phase 1: subject must have received =1 prior line of systemic anticancer therapy considered to be Standard of Care per the Investigator's judgment, in the metastatic or unresectable setting b. Phase 2: i. Arm A: subject must have received only 1-2 prior lines of systemic anticancer therapy considered to be Standard of Care per the Investigator's judgment, in the metastatic or unresectable setting ii. Arm B: subject must have received =1 prior line of systemic anticancer therapy considered to be Standard of Care per the Investigator's judgment, in the metastatic or unresectable setting 3. Subject must be: - =18 years of age (no minimum weight), - =16 and <18 years old and weighs =50 kg, - =12 and <16 years of age and weighs =40kg, - or =16 and <18 years of age and weighs =40kg and <50kg 4. Subject must be able to safely swallow capsules 5. Subject must have measurable disease as defined by RECIST v1.1 6. Subject must have Eastern Cooperative Oncology Group performance status =2 or Lansky performance scale (LK scale) = 60 7. Subject must have adequate organ function, defined as: 1. Bone marrow function: absolute neutrophil count =1.0 x 109/L independent of growth factor support for =7 days prior to first dose of study drug for granulocyte colony-stimulating factor and =14 days prior to first dose of study drug for peg-filgrastim; hemoglobin =8 g/dL independent of transfusion support for =7 days prior to first dose of study drug; platelet count =75 x 109 /L independent of transfusion support for =3 days prior to first dose of study drug 2. Coagulation: Prothrombin time (PT)/international normalized ratio (INR) <1.5x the upper limit of normal (ULN) and activated partial thromboplastin time (aPTT) <1.5x ULN (unless the subject is receiving anticoagulant therapy and INR and partial PT/aPTT are within therapeutic range of intended use of anticoagulants) 3. Liver function: total bilirubin =1.5x ULN (=3.0x ULN for subjects with Gilbert's syndrome), aminotransferase (ALT) and aspartate aminotransferase (AST) =3.0x ULN; except for subjects who have tumor infiltration of the liver, where ALT and AST =5x ULN 4. Renal function: must have a creatinine clearance =60 mL/min (via Cockcroft-Gault equation, institutional standard, or measured) 5. Cardiac function: baseline corrected QT interval using Fredericia's formula =470 ms (adolescents 12-17 years of age: =450 ms) and a left ventricular ejection fraction =50% evaluated via echocardiogram or multi-gated acquisition (MUGA) scan 8. Availability of archival tumor tissue sample or newly obtained core/excisional biopsy of a tumor not previously irradiated 9. A female subject may be eligible to participate if she is not pregnant or planning a pregnancy, not breastfeeding, and following protocol mediated guidance to avoid pregnancy 10. A male subject must have had a prior vasectomy and agree to use a condom during the treatment period and for at least 90 days after the last dose of study treatment 11. A male subject must refrain from donating sperm while taking CFT8634 and for 90 days post-last dose 12. A female subject must refrain from donating ova while taking CFT8634 and for 180 days after discontinuation 13. All subjects must refrain from donating blood and blood products while receiving study drug and for 30 days post-last dose Exclusion Criteria: 1. Subject has had major surgery within 21 days prior to the planned first dose of CFT8634 a. Minor surgery (eg, minor biopsy of extracranial site, central venous catheter placement, shunt revision) is permitted within 21 days prior to first dose of CFT8634 2. Subject has received standard of care or investigational systemic anti-neoplastic therapy within 14 days or 5 half-lives, whichever is shorter, prior to the planned first dose of CFT8634 3. Subject has received radiation therapy within 14 days prior to the planned first dose of CFT8634 4. Prior treatment with BRD9 degrader 5. Subject has central nervous system (CNS) involvement (primary tumor or metastatic disease), except in the following circumstances: 1. Subjects with previously treated brain metastases may be permitted to participate provided they are stable (without evidence of progression by imaging 14 days prior to the first dose of study drug and any neurologic symptoms have stabilized), have no evidence of new or enlarging brain metastases, and if they are taking corticosteroids, they are on stable or tapering doses for at least 7 days prior to first dose of study drug. Antiseizure therapy is permitted provided the medication is not otherwise excluded and seizures have been controlled for at least 28 days since the last antiseizure medication adjustment 2. Subjects with asymptomatic brain metastases found on Screening magnetic resonance imaging (MRI) may be permitted to be entered into the study without prior radiation therapy to the brain if they do not require immediate surgical or radiation therapy in the opinion of the treating investigator and in the opinion of a radiation therapy or neurosurgical consultant 6. Subject has any evidence of a CNS bleed including intra-tumoral hemorrhage 7. Subject has known bleeding diathesis 8. Subject has impaired cardiac function or clinically significant cardiac disease (i.e. uncontrolled heart disease/hypertension, clinically significant arrythmias, unstable angina/myocardia infarction/stroke within 180 days prior to screening) 9. Subject with presence of inflammatory vascular disease or microangiopathy (eg, thrombotic microangiopathies, hemolytic uremic syndrome [HUS], atypical HUS) 10. Subject with known malignancy, other than study indication, that is progressing or has required treatment within the past 3 years a. Subject with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (i.e. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded 11. Subject has received live, attenuated vaccine within 28 days prior to first dose administration 12. Subject with known history of human immunodeficiency virus (HIV) infection 13. Subject had a venous thrombosis within 14 days prior to first dose of study drug 14. Subject with gastrointestinal absorption issues (e.g., malabsorption syndrome or other illness that could affect oral absorption). 15. Concurrent administration of strong cytochrome P450 (CYP) 3A4 inhibitors and inducers, and multidrug resistance mutation 1 (MDR1) inhibitors.

Study Design


Intervention

Drug:
CFT8634
Oral dose of CFT8634

Locations

Country Name City State
United States University of Colorado - Aurora Cancer Center Aurora Colorado
United States Massachusetts General Hospital Boston Massachusetts
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States City of Hope Duarte California
United States MD Anderson Cancer Center Houston Texas
United States University of Iowa Hospital and Clinics Iowa City Iowa
United States Mayo Clinic - Jacksonville Jacksonville Florida
United States Columbia University New York New York
United States David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center New York New York
United States Mayo Clinic - Rochester Rochester Minnesota
United States Washington University School of Medicine Saint Louis Missouri
United States Sarcoma Oncology Research Center Santa Monica California

Sponsors (1)

Lead Sponsor Collaborator
C4 Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency and severity of AEs and serious adverse events (SAEs) Phase 1 and Phase 2 From screening until at least 30 days after completion of study treatment
Primary Number of subjects with changes between baseline and post-baseline safety assessments based on safety laboratory results graded by CTCAE v5.0 Phase 1 and Phase 2 From screening until at least 30 days after completion of study treatment
Primary Frequency of dose interruptions and dose reductions Phase 1 and Phase 2 From first dose until end of treatment
Primary Incidence of dose limiting toxicities (DLTs) Phase 1 only From first dose until 28 days after first dose
Primary Overall Response Rate (ORR) Phase 2 only according to RECIST v1.1 criteria Up to approximately 24 months
Secondary Plasma concentration of CFT8634 to characterize the pharmacokinetics (PK) parameters of CFT8634 Plasma concentration of CFT8634 at the scheduled timepoints At multiple time points up to approximately 24 weeks
Secondary Asses dose proportionality assessment Dose proportionately assessment at the scheduled timepoints At multiple time points up to approximately 24 weeks
Secondary Assess the pharmacodynamics by percent reduction from baseline of target protein Tumor BRD9 degradation at scheduled timepoints At multiple time points up to approximately 24 weeks
Secondary ORR Phase 1 only according to RECIST v1.1 criteria Up to approximately 24 months
Secondary Duration of Response (DOR) DOR defined as time from first assessment of PR or CR to follow-on first assessment of progressive disease (PD) Up to approximately 24 months
Secondary Progression Free Survival (PFS) PFS defined as the time from first treatment received until PD is assessed Up to approximately 24 months
Secondary Overall Survival (OS) OS is defined as the time from first dose of study treatment to the date of death, irrespective of the cause of death. (Phase 2 only) Up to approximately 48 months
Secondary Time to next treatment Interval from the date of initiation of a treatment to the date of commencement of the next line of therapy Up to approximately 8 months
See also
  Status Clinical Trial Phase
Recruiting NCT02910895 - A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS) N/A
Recruiting NCT05621668 - A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma Phase 1
Active, not recruiting NCT04032964 - Dose Finding Study of L19TNF and Doxorubicin in Patients With STS Phase 1
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Completed NCT01650077 - Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2
Terminated NCT02890368 - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Phase 1
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Completed NCT02204111 - Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma
Withdrawn NCT01663090 - Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas N/A
Completed NCT01259375 - Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma Phase 2
Completed NCT01440088 - A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Phase 3
Completed NCT01106872 - Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas Phase 1
Recruiting NCT00753727 - Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma Phase 1/Phase 2
Terminated NCT00755261 - Phase II Study of Doxorubicin and Avastin® in Sarcoma. Phase 2
Completed NCT00611078 - Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study N/A
Completed NCT00580320 - Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma Phase 1
Completed NCT03452644 - US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors
Recruiting NCT05539677 - Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Terminated NCT03520959 - A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) Phase 3